EFFECTS OF THERAPY WITH VERAPAMIL AND ITS COMBINATIONS WITH DIURETICS ON BLOOD PRESSURE AND LIPID PROFILE IN HYPERTENSIVE PATIENTS
https://doi.org/10.29001/2073-8552-2015-30-3-45-49
Abstract
The aim of this study was to elucidate the effects of long term therapy with verapamil and its combinations with diuretics on blood pressure and lipid metabolism in hypertensive patients. We studied 26 hypertensive patients. The following parameters were estimated: 24-hours ambulatory blood pressure monitoring (ABPM), plasma levels of the lipids and glucose. All parameters were evaluated before and after 6-month therapy. Goal BP was achieved in 54% of patients with monotherapy by verapamil and in 96% of patients treated by combination of verapamil and diuretics. Moreover, after 6 month, there was a decrease in LDL levels both in patients with monotherapy and with combination of verapamil and diuretics. According to our data, therapy with verapamil in hypertensive patients demonstrated good profile of tolerance, significant antihypertensive effect, and improved lipid metabolism even after diuretic adding.
About the Authors
A. Yu. Falkovskaya
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
V. F. Mordovin
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
I. V. Zyubanova
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
T. E. Suslova
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
References
1. Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии // Consilium medicum. - 2006. - Т. 8, № 11. - C. 113-117.
2. Bonaa K.H., Thelle D.S. Association between blood pressure and serum lipids in a population. The Tromso Study // Circulation. - 1991. - Vol. 83. - P. 1305-1314.
3. Bangalore S., Messerli F.H., Cohen J.D. et al. INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy // Am. Heart J. - 2008. - Vol. 156(2). - P. 241-247.
4. Gillman M.W., Kannel W.B., Belanger A., D’Agostino R.B. Influence of heart rate on mortality among persons with hypertension: The Framingham Study // Am. Heart J. - 1993. - Vol. 125(4). - P. 1148-1154.
5. Gillum R.F., Makuc D.M., Feldman J.J. Pulse rate, coronary heart disease and death: the NHANES-1 Epidemiologic follow-up study // Am. Heart J. - 1991. - Vol. 121. - P. 172-177.
6. Julius S., Jamerson K., Mejia A. et al. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure study // JAMA. - 1990. - Vol. 264. - P. 354-358.
7. Lefrandt J.D., Urbigkelt A., Sevre K. et al. Improved short-term blood pressure control by treatment with calcium antagonists in patients with mild to moderate hypertension // Am. J. Hypertension. - 1999. - Vol. 12(S4). - P. 130A.
8. Libretti A., Catalano M. Lipid profile during antihypertensive treatment / SLIP study group // Drugs. - 1993. - Vol. 46, issue 2 (suppl.). - P. 16-23.
9. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25. - P. 1105-1187.
10. Nauman J., Janszky I., Vatten L.J., Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease // JAMA. - 2011. - Vol. 306(23). - P. 2579-2587.
11. Sacks F.M., Dzau V.J. Adrencrgic effects on plasma lipoprotein metabolism: Speculation on mechanisms of action // Am. J. Med. - 1986. - Vol. 80 (Suppl. 2A). - P. 71-81.
12. Stevo J. Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension // Hypertension. - 1993. - Vol. 21. - P. 886-893.
13. Suter P.M., Vetter W. Metabolic effects of antihypertensive drugs // J. Hypertens. - 1995. - Vol. 13(4), suppl. - P. S11-S17.
14. Yamakado M., Shimomura H., Maehata E. et al. Clinical study on antiatherogenic properties of lacidipine in patients with essential hypertension // Eur. Meeting on Calcium Antagonists. - Amsterdam, 1993.
Review
For citations:
Falkovskaya A.Yu., Mordovin V.F., Zyubanova I.V., Suslova T.E. EFFECTS OF THERAPY WITH VERAPAMIL AND ITS COMBINATIONS WITH DIURETICS ON BLOOD PRESSURE AND LIPID PROFILE IN HYPERTENSIVE PATIENTS. Siberian Journal of Clinical and Experimental Medicine. 2015;30(3):45-49. (In Russ.) https://doi.org/10.29001/2073-8552-2015-30-3-45-49
Views:
1140
.png)
Email this article 